Ondansetron

Jun 26, 2019

Breast Cancer Surgery: Avoiding-Minimizing Post-operative Nausea

Apr 18, 2018

Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting

Apr 10, 2018

Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

Mar 26, 2018

GT Biopharma, Inc. Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial

Jan 09, 2018

GT Biopharma Announces Completion of Dosing in Phase 1 Clinical Trial of GTP-004 for Myasthenia Gravis

Jan 04, 2018

Acacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS® for the Management of Post-operative Nausea & Vomiting

Oct 05, 2017

Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)